Biotechnology

A new deal between genomics giant Illumina and startup Bifrost Biosystems isn't just a business transaction. It’s a strategic play to rewire the very process of drug discovery.

Supplement giant Niagen Bioscience is betting big on a new drug for a rare disease. Can its NAD+ science make the leap from wellness to a real cure?

GeneCentric's ExpressCT Rewind™ uses fragmentomics to mine gene expression data from old liquid biopsies, offering a cost-effective way to find new biomarkers.

With bladder cancer recurrence rates stubbornly high, UroGen Pharma is advancing a novel oncolytic virus into human trials. Can it finally break the cycle?

Evogene and Tel Aviv University are pairing generative AI with lab validation to bridge the 'valley of death' for academic drug research in Israel.

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

Bio-Techne's new AI-designed proteins tackle a critical hurdle in regenerative medicine: scalable manufacturing. This is how digital tools are industrializing biology.

China's top probiotics firm, WONDERLAB, is challenging the 'calories in, calories out' model with a new framework for precision, microbiome-based weight loss.

Avacta taps veteran dealmaker Dr. Patrick Vink as it nears a pivotal data reveal for its pre|CISION® platform, signaling a shift from R&D to high-stakes commercial strategy.

For children with the rare metabolic disorder MMA, a new gene therapy offers hope. Preclinical data reveals a potential one-time fix with lifelong effects.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?

MEDIPOST's Phase III trial for knee osteoarthritis isn't just a medical milestone; it's a test case for a faster regulatory path using global data.

A new deal to develop cancer drugs reveals a seismic shift: China is no longer just a market, but a core engine in a new global innovation network.

Seattle-based A-Alpha Bio just launched Atlas, a platform that doesn't just design drugs with AI, but generates the massive datasets needed to make AI work.

A new company aims to fix a multi-billion dollar problem in drug development by using advanced biomarker tests to find the right patients before they even start.

With €33M in fresh capital, Cyllene Therapeutics is advancing a novel gene therapy for bladder disease. We analyze the tech, the investors, and the plan.

A new partnership brings autonomous AI agents to the lab, promising to slash drug development timelines. But can these 'AI scientists' be trusted with our future medicines?

Nanoscope's revolutionary MCO-010 gene therapy offers hope to millions with retinal disease. A new partnership with Catalent is the critical final step.

Cytokinetics is set to unveil groundbreaking data for aficamten, a therapy that could become the first-ever approved treatment for non-obstructive HCM.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.